Newer Targeted Approaches in Medullary Thyroid Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.

Manisha Shah_re-do
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.

      Recent Videos
      Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
      Taste Change Data May Inform Radiotherapy Strategy in Head and Neck Cancer
      Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
      Data Show Substantial Taste Changes in Head and Neck Cancer Following RT
      Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
      Measuring Objective Taste Changes in Head and Neck Cancer Population After RT
      Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
      Advocate Outlines Resources for Chronic Myeloid Leukemia Population
      Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
      Assessing the Future With “Promising” Antibody Drug Conjugates in Breast Cancer
      Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
      Mitigating ILD Following T-DXd in HR+, HER2-Low Metastatic Breast Cancer
      Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
      Ensuring Quality of Life in Chronic Myeloid Leukemia Populations
      Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
      Formulating Questions for Clinicians to Understand a CML Diagnosis
      Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
      Defining Goals of Therapy in Chronic Myeloid Leukemia
      Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
      Mitigating Toxicity and Monitoring QOL in Chronic Myeloid Leukemia
      Related Content
      A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

      Aggressive Thyroid Screening/Treatment Not Associated With Higher Survival

      Roman Fabbricatore
      February 9th 2025
      Article

      A population-based study led by Cedars-Sinai investigators found that thyroid cancer continues to be overdiagnosed, while the risk of dying from the disease has remained the same.

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

      Neil M. Iyengar, MD;Paolo Tarantino, MD
      June 17th 2024
      Podcast

      Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

      Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

      Durvalumab Does Not Improve Outcomes Vs Cetuximab in Head and Neck Cancer

      Tim Cortese
      December 1st 2024
      Article

      For patients with head and neck squamous cell carcinoma and contraindications to cisplatin, durvalumab yielded worse PFS vs cetuximab.

      Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

      Oncology On-The-Go Podcast: ASCO 2023 Recap

      Ritu Salani, MD;Tanios S. Bekaii-Saab, MD, FACP
      June 19th 2023
      Podcast

      Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

      While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

      Cisplatin Shortage Shifted Chemo Utilization to Costlier Therapies for HNC

      Roman Fabbricatore
      October 16th 2024
      Article

      While cisplatin was in shortage, clinicians were forced to prescribe costlier alternatives for patients with head and neck cancer.

      Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

      Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

      Russ Conroy
      October 8th 2024
      Article

      Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.